These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31765733)

  • 41. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.
    Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U
    Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
    Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
    Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor localization of an anti-TGF-β antibody and its effects on gliomas.
    Hülper P; Schulz-Schaeffer W; Dullin C; Hoffmann P; Harper J; Kurtzberg L; Lonning S; Kugler W; Lakomek M; Erdlenbruch B
    Int J Oncol; 2011 Jan; 38(1):51-9. PubMed ID: 21109925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
    Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
    Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma.
    Shevtsov MA; Nikolaev BP; Yakovleva LY; Parr MA; Marchenko YY; Eliseev I; Yudenko A; Dobrodumov AV; Zlobina O; Zhakhov A; Ischenko AM; Pitkin E; Multhoff G
    J Control Release; 2015 Dec; 220(Pt A):329-340. PubMed ID: 26522072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
    Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
    Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
    Lan T; Zhao Z; Qu Y; Zhang M; Wang H; Zhang Z; Zhou W; Fan X; Yu C; Zhan Q; Song Y
    Oncotarget; 2016 Aug; 7(34):55555-55571. PubMed ID: 27487130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
    Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
    BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse.
    Natsume A; Mizuno M; Ryuke Y; Yoshida J
    Gene Ther; 1999 Sep; 6(9):1626-33. PubMed ID: 10490773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Parra K; Valenzuela P; Lerma N; Gallegos A; Reza LC; Rodriguez G; Emmenegger U; Di Desidero T; Bocci G; Felder MS; Manciu M; Kirken RA; Francia G
    Br J Cancer; 2017 Jan; 116(3):324-334. PubMed ID: 28056464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.
    Beck BH; Kim H; O'Brien R; Jadus MR; Gillespie GY; Cloud GA; Hoa NT; Langford CP; Lopez RD; Harkins LE; Lamb LS
    PLoS One; 2015; 10(5):e0122387. PubMed ID: 25955158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report.
    Wolff JE; Boos J; Krähling KH; Jürgens H
    Klin Padiatr; 1996; 208(4):190-2. PubMed ID: 8776706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
    Galstyan A; Markman JL; Shatalova ES; Chiechi A; Korman AJ; Patil R; Klymyshyn D; Tourtellotte WG; Israel LL; Braubach O; Ljubimov VA; Mashouf LA; Ramesh A; Grodzinski ZB; Penichet ML; Black KL; Holler E; Sun T; Ding H; Ljubimov AV; Ljubimova JY
    Nat Commun; 2019 Aug; 10(1):3850. PubMed ID: 31462642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway.
    Alicea-Torres K; Sanseviero E; Gui J; Chen J; Veglia F; Yu Q; Donthireddy L; Kossenkov A; Lin C; Fu S; Mulligan C; Nam B; Masters G; Denstman F; Bennett J; Hockstein N; Rynda-Apple A; Nefedova Y; Fuchs SY; Gabrilovich DI
    Nat Commun; 2021 Mar; 12(1):1717. PubMed ID: 33741967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma.
    Natsume A; Tsujimura K; Mizuno M; Takahashi T; Yoshida J
    J Neurooncol; 2000 Apr; 47(2):117-24. PubMed ID: 10982152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.